Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
about
Recent advances in the management of Hodgkin lymphomaClinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated ReviewCyanobacterial Metabolite Calothrixins: Recent Advances in Synthesis and Biological EvaluationStrategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer TherapeuticsPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyDiagnostic, prognostic and therapeutic role of CD30 in lymphoma.Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.Immunotherapy in hematologic malignancies: past, present, and future.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesNovel systemic therapy against malignant pleural mesothelioma.Hodgkin's lymphoma (relapsed or refractory): autologous stem cell therapy.Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.CAR-T Cell Therapy for Lymphoma.Severe Acute Pulmonary Toxicity Associated with Brentuximab in a Patient with Refractory Hodgkin's LymphomaSingle or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature.Impact of the microbial derived short chain fatty acid propionate on host susceptibility to bacterial and fungal infections in vivo.Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?Meta-analysis on autologous stem cell transplantation in the treatment of limb ischemic.Chimeric antigen receptor T-cell therapies for lymphoma.Emerging antibody-drug conjugates for treating lymphoid malignancies.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Antibody-mediated delivery of therapeutics for cancer therapy.CD30 Expression in Pediatric Neoplasms, Study of 585 Cases.Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumabThe evolving role of targeted drugs in the treatment of Hodgkin lymphoma.Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.Immunotherapy for the treatment of Hodgkin lymphoma.Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.Recent treatment advances in Hodgkin lymphoma: a concise review.Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management.Emerging drugs for graft-versus-host disease.The emerging role of immune checkpoint inhibition in malignant lymphoma.
P2860
Q26751214-EE905B9C-F10F-49BB-AE54-303DB27C65B2Q26770716-6EA8BD80-2A63-44F4-B98F-6CA149635156Q26771720-7D0B9686-EB69-4616-88AE-662530EF5788Q26780335-E9853C25-C3B2-4B52-B9D1-FBCDC3384439Q28070090-73D54B8C-FCE3-4AA0-80C5-84A5A85D25E7Q30240160-0EB65C65-B7D5-46D6-AC8E-5E5C051BDCE2Q30248284-A0211C05-F2FA-417A-B0C1-3E8E437A39F7Q33442755-46BE7FD0-1A6F-42E7-87B9-36272A2EA11BQ33593865-0EA09E4A-558C-4CEC-8EFF-B8A544690A72Q33704061-4322D3C6-71C1-4C54-83DF-E9BEA4B40C79Q33886267-5746BFF3-87F6-4DE2-A815-6465326890E1Q33890499-7402D609-54DB-4E6D-B49C-2548F019F759Q35821412-C857844B-2E86-4498-8309-71FB75BEFF44Q36356089-5FFCBEC3-1E3D-430F-8B26-2F4272AA9BB6Q36519358-26090E4E-039C-4038-94B3-E28D67FCCE10Q36854771-C3ED0AD4-608C-46F6-B8E7-059A7D8AC2B7Q37216339-2502C1FF-B208-434E-8275-547C0845A641Q37363925-88D7ECD7-8555-4B50-B729-3C970C4C0DC4Q37448992-153ED394-3761-4DAF-AA8C-13D77582BD1DQ37672032-C9E9CB48-2A62-46E3-A9D9-A640CB7D55EAQ38568358-808BA62D-5B54-4BDA-ADF7-0647B8E90D53Q38574304-F3FED204-FBAF-49A3-B3A3-864AC444F822Q38600697-BF83643E-49D7-4B21-8490-0ACA7DD8287EQ38632313-95921C87-718B-4195-A0A3-223BBDECBE81Q38664909-F05EF033-3C21-4C86-AC01-CC2EE0B04EB6Q38665425-A94D9B12-A600-4BD9-BB5B-D6DBDF9A7E0BQ38682195-42BA1B7C-832D-4732-A71E-047E66596CD4Q38684561-CE57FF42-533E-45AB-9EBE-F13EED7085CDQ38687582-A0AE3933-DE9D-4529-818D-8AF5A9F2A1E9Q38700459-71EED98B-ACA3-45B0-99F6-76A479ED2FFAQ38707852-3CA4C5C6-3EEE-4C82-9E26-F49E2D6F0522Q38721642-D0C53DAD-9FA3-416C-B7A2-E6B10709F0DCQ38737641-B97D1CE7-CB38-4018-BAC6-BCB7D5940E00Q38741693-0A3900D0-9774-4745-A404-019B7993279DQ38755955-BEFF7FDC-A08A-4363-99B0-43D70CD14777Q38775871-804B00CA-04A2-42F2-80DC-DA4FDEA37215Q38781590-DF956205-61EC-4A69-90BD-A5EC3C1C9E59Q38784099-1E456058-32C8-4D9C-B722-C0878656DC90Q38786084-E551F588-E068-4F99-A19C-9C17A2B5770EQ38791036-1452C1FA-1C34-4C48-8472-ABAA33B4C6F4
P2860
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Brentuximab vedotin as consoli ...... ebo-controlled, phase 3 trial.
@en
type
label
Brentuximab vedotin as consoli ...... ebo-controlled, phase 3 trial.
@en
prefLabel
Brentuximab vedotin as consoli ...... ebo-controlled, phase 3 trial.
@en
P2093
P50
P1433
P1476
Brentuximab vedotin as consoli ...... cebo-controlled, phase 3 trial
@en
P2093
AETHERA Study Group
Alessandro M Gianni
Andy I Chen
Angelo Carella
Anna Sureda
Auayporn Nademanee
Craig H Moskowitz
Dirk Huebner
Dzhelil Osmanov
P304
P356
10.1016/S0140-6736(15)60165-9
P407
P577
2015-03-19T00:00:00Z